Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure

Broch, Kaspar; Andreassen, Arne K.; Ueland, Thor; Michelsen, Annika E.; Stueflotten, Wenche; Aukrust, Pål; Aakhus, Svend; Gullestad, Lars

doi:10.1016/j.ijcard.2014.11.003

Cited by 31 publications

(28 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While most research has focussed on the prognostic value of sST2 in patients with left ventricular failure (Ky et al Associations between the natural logarithm of the serum concentration of soluble ST2 and clinical and echocardiographic parameters. 2011, Broch et al 2012), circumstantial evidence implies that sST2 might be a measure of congestion (Bartunek et al 2008, Broch et al 2015, and therefore might be associated with right ventricular failure as much as with left ventricular failure. Our results suggest that sST2 reflects right ventricular failure in patients with ARVC.…”

Section: Discussionmentioning

confidence: 99%

“…Circulating levels of sST2 are associated with outcome in patients with left heart failure (Ky et al 2011, Broch et al 2012, Llibre et al 2016. However, elevated levels of sST2 observed in these patients may stem from endothelial release of sST2 in response to congestion (Bartunek et al 2008, Demyanets et al 2013, Broch et al 2015. Thus, plasma sST2 may mirror not only left ventricular function, but also the degree of right ventricular failure, as observed in patients with pulmonary arterial hypertension (Carlomagno et al 2013, Zheng et al 2014.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Soluble ST2 is associated with disease severity in arrhythmogenic right ventricular cardiomyopathy

et al. 2017

Self Cite

View full text Add to dashboard Cite

Purpose: Diagnostic and prognostic evaluation remains challenging in arrhythmogenic right ventricular cardiomyopathy (ARVC). We measured plasma concentration of soluble ST2 (sST2) and assessed its association with right ventricular (RV) function and ventricular arrhythmias in patients with ARVC. Methods: We included patients with ARVC and genotype positive relatives. Soluble ST2 was determined by ELISA. We assessed myocardial function by echocardiography including strain by speckle tracking technique. Results: We included 44 subjects (age 41 ± 15 years, 21 (48%) female). Soluble ST2 was associated with RV global strain (r ¼ 0.44; p ¼ 0.008), as well as with left ventricular (LV) function. Plasma levels of sST2 were higher in patients with ventricular arrhythmias than in patients without ventricular arrhythmias (35 ± 13 ng/mL vs. 26 ± 7 ng/mL, p ¼ 0.009). The association between sST2 and ventricular arrhythmias remained significant even after adjusting for RV function (Wald ¼ 5.2; p ¼ 0.02). Conclusions: Soluble ST2 is associated with RV and LV function in patients with ARVC. Soluble ST2 may aid in the determination of disease severity in ARVC.ARTICLE HISTORY

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Soluble ST2 is associated with disease severity in arrhythmogenic right ventricular cardiomyopathy

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Study population 1 (Table 1) consisted of 102 patients with a diagnosis of idiopathic DCM and has been described in detail previously 51 . At baseline, the patients underwent physical examination; blood tests; echocardiography; cardiac magnetic resonance imaging (MRI) and right-sided cardiac catheterization.…”

Section: Methodsmentioning

confidence: 99%

Wnt5a is associated with right ventricular dysfunction and adverse outcome in dilated cardiomyopathy

Abraityte

Lunde

Askevold

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

The Wingless (Wnt) pathway has been implicated in the pathogenesis of dilated cardiomyopathy (DCM). To explore the role of Wnt modulators Wnt5a and sFRP3 in DCM patients we analyzed the expression of Wnt5a and sFRP3 in plasma and myocardium of DCM patients and evaluated their effects on NFAT luciferase activity in neonatal mouse cardiomyocytes. Elevated circulating Wnt5a (n = 102) was associated with increased pulmonary artery pressures, decreased right ventricular function and adverse outcome, with a stronger association in more severely affected patients. A higher Wnt5a/sFRP3 ratio (n = 25) was found in the right ventricle vs. the left ventricle and was correlated with NFAT activation as well as pulmonary artery pressures. Wnt5a induced NFAT activation and sFRP3 release in cardiomyocytes in vitro, while sFRP3 antagonized Wnt5a. Wnt5a is associated with right ventricular dysfunction and adverse outcome in DCM patients and may promote the progression of DCM through NFAT signaling.

show abstract

“…In addition, the study by Ahmad et al demonstrated that sST2 was a better prognostic marker for heart failure than for sudden cardiac death 37. Thus, the prognostic value of sST2 might be its ability to predict heart failure, rather than fatal VTs in patients with non‐ischaemic DCM 46, 48…”

Section: Discussionmentioning

confidence: 99%

GDF‐15 is a better complimentary marker for risk stratification of arrhythmic death in non‐ischaemic, dilated cardiomyopathy than soluble ST2

Stojković

Kaider

Koller

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

Growth differentiation factor (GDF)‐15 and soluble ST2 (sST2) are established prognostic markers in acute and chronic heart failure. Assessment of these biomarkers might improve arrhythmic risk stratification of patients with non‐ischaemic, dilated cardiomyopathy (DCM) based on left ventricular ejection fraction (LVEF). We studied the prognostic value of GDF‐15 and sST2 for prediction of arrhythmic death (AD) and all‐cause mortality in patients with DCM. We prospectively enrolled 52 patients with DCM and LVEF ≤ 50%. Primary end‐points were time to AD or resuscitated cardiac arrest (RCA), and secondary end‐point was all‐cause mortality. The median follow‐up time was 7 years. A cardiac death was observed in 20 patients, where 10 patients had an AD and 2 patients had a RCA. One patient died a non‐cardiac death. GDF‐15, but not sST2, was associated with increased risk of the AD/RCA with a hazard ratio (HR) of 2.1 (95% CI = 1.1‐4.3; P = .031). GDF‐15 remained an independent predictor of AD/RCA after adjustment for LVEF with adjusted HR of 2.2 (95% CI = 1.1‐4.5; P = .028). Both GDF‐15 and sST2 were independent predictors of all‐cause mortality (adjusted HR = 2.4; 95% CI = 1.4‐4.2; P = .003 vs HR = 1.6; 95% CI = 1.05‐2.7; P = .030). In a model including GDF‐15, sST2, LVEF and NYHA functional class, only GDF‐15 was significantly associated with the secondary end‐point (adjusted HR = 2.2; 95% CI = 1.05‐5.2; P = .038). GDF‐15 is superior to sST2 in prediction of fatal arrhythmic events and all‐cause mortality in DCM. Assessment of GDF‐15 could provide additional information on top of LVEF and help identifying patients at risk of arrhythmic death.

show abstract

Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure

Cited by 31 publications

References 21 publications

Soluble ST2 is associated with disease severity in arrhythmogenic right ventricular cardiomyopathy

Soluble ST2 is associated with disease severity in arrhythmogenic right ventricular cardiomyopathy

Wnt5a is associated with right ventricular dysfunction and adverse outcome in dilated cardiomyopathy

GDF‐15 is a better complimentary marker for risk stratification of arrhythmic death in non‐ischaemic, dilated cardiomyopathy than soluble ST2

Contact Info

Product

Resources

About